<page><title>Rubinstein-Taybi syndrome</title><url>https://medlineplus.gov/genetics/condition/rubinstein-taybi-syndrome</url><content>Rubinstein-Taybi syndrome
To use the sharing features on this page, please enable JavaScript.
Description
Rubinstein-Taybi syndrome is a condition characterized by short stature, moderate to severe intellectual disability, distinctive facial features, and
broad thumbs
and
first toes
. Additional features of the disorder can include eye abnormalities, heart and kidney defects, dental problems, and obesity. These signs and symptoms vary among affected individuals. People with this condition have an increased risk of developing particular types of noncancerous brain and skin tumors.
Frequency
Rubinstein-Taybi syndrome is uncommon; it occurs in an estimated 1 in 100,000 to 125,000 newborns.
Causes
Mutations in the
CREBBP
gene cause about half of cases of Rubinstein-Taybi syndrome. The
CREBBP
gene provides instructions for making a protein that helps control the activity of many other genes. This protein, called CREB binding protein, plays an important role in regulating cell growth and division and is essential for normal development before birth. Because one copy of the
CREBBP
gene is deleted or mutated in people with Rubinstein-Taybi syndrome, their cells make only half of the normal amount of CREB binding protein. A reduction in the amount of this protein disrupts normal development before and after birth. Abnormal brain development is thought to underlie intellectual disability in people with Rubinstein-Taybi syndrome. Researchers have not determined how
CREBBP
gene mutations lead to other signs and symptoms of Rubinstein-Taybi syndrome.
Mutations in the
EP300
gene cause a small percentage of cases of Rubinstein-Taybi syndrome. Like the
CREBBP
gene, this gene provides instructions for making a protein that helps control the activity of other genes. It also appears to be important for development before and after birth.
EP300
gene mutations result in the loss of one functional copy of the gene in each cell, which interferes with normal development and causes the typical features of Rubinstein-Taybi syndrome. The signs and symptoms of this disorder caused by
EP300
gene mutations are typically milder than those caused by mutations in the
CREBBP
gene.
Several cases of severe Rubinstein-Taybi syndrome have resulted from a
deletion
of genetic material from the short (p) arm of
chromosome 16
. Multiple genes, including the
CREBBP
gene, are missing as a result of this deletion. Researchers believe that the loss of multiple genes in this region probably accounts for the serious complications associated with severe Rubinstein-Taybi syndrome. Some researchers suggest that these cases are a separate condition called chromosome 16p13.3 deletion syndrome. However, a few studies indicate that some people with large deletions in the same region of chromosome 16 have characteristic features of Rubinstein-Taybi syndrome rather than a more severe condition.
Nearly 30 to 40 percent of people with Rubinstein-Taybi syndrome do not have an identified mutation in the
CREBBP
or
EP300
gene or a chromosome 16 deletion. The cause of the condition is unknown in these cases. Researchers predict that mutations in other genes can also cause the disorder.
Learn more about the genes and chromosome associated with Rubinstein-Taybi syndrome
CREBBP
EP300
chromosome 16
Inheritance
This condition is considered to have an
autosomal dominant pattern
of inheritance, which means one copy of the altered gene in each cell is sufficient to cause the disorder. Most cases result from new mutations in the gene and occur in people with no history of the disorder in their family.
Other Names for This Condition
Broad thumb-hallux syndrome
RSTS
RTS
Additional Information &amp; Resources
Genetic Testing Information
Genetic Testing Registry: Rubinstein-Taybi syndrome due to CREBBP mutations
Genetic Testing Registry: Rubinstein-Taybi syndrome due to EP300 haploinsufficiency
Genetic and Rare Diseases Information Center
Rubinstein-Taybi syndrome
Patient Support and Advocacy Resources
National Organization for Rare Disorders (NORD)
Clinical Trials
ClinicalTrials.gov
Catalog of Genes and Diseases from OMIM
RUBINSTEIN-TAYBI SYNDROME 1; RSTS1
RUBINSTEIN-TAYBI SYNDROME 2; RSTS2
Scientific Articles on PubMed
PubMed
References
Bartholdi D, Roelfsema JH, Papadia F, Breuning MH, Niedrist D, Hennekam RC,
Schinzel A, Peters DJ. Genetic heterogeneity in Rubinstein-Taybi syndrome:
delineation of the phenotype of the first patients carrying mutations in EP300. J
Med Genet. 2007 May;44(5):327-33. doi: 10.1136/jmg.2006.046698. Epub 2007 Jan 12.
Citation on PubMed
or
Free article on PubMed Central
Bartsch O, Rasi S, Delicado A, Dyack S, Neumann LM, Seemanova E, Volleth M,
Haaf T, Kalscheuer VM. Evidence for a new contiguous gene syndrome, the
chromosome 16p13.3 deletion syndrome alias severe Rubinstein-Taybi syndrome. Hum
Genet. 2006 Sep;120(2):179-86. doi: 10.1007/s00439-006-0215-0. Epub 2006 Jun 17.
Citation on PubMed
Bartsch O, Schmidt S, Richter M, Morlot S, Seemanova E, Wiebe G, Rasi S. DNA
sequencing of CREBBP demonstrates mutations in 56% of patients with
Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS. Hum
Genet. 2005 Sep;117(5):485-93. doi: 10.1007/s00439-005-1331-y. Epub 2005 Jul 14.
Citation on PubMed
Bentivegna A, Milani D, Gervasini C, Castronovo P, Mottadelli F, Manzini S,
Colapietro P, Giordano L, Atzeri F, Divizia MT, Uzielli ML, Neri G, Bedeschi MF,
Faravelli F, Selicorni A, Larizza L. Rubinstein-Taybi Syndrome: spectrum of
CREBBP mutations in Italian patients. BMC Med Genet. 2006 Oct 19;7:77. doi:
10.1186/1471-2350-7-77.
Citation on PubMed
or
Free article on PubMed Central
Coupry I, Roudaut C, Stef M, Delrue MA, Marche M, Burgelin I, Taine L, Cruaud
C, Lacombe D, Arveiler B. Molecular analysis of the CBP gene in 60 patients with
Rubinstein-Taybi syndrome. J Med Genet. 2002 Jun;39(6):415-21. doi:
10.1136/jmg.39.6.415. No abstract available.
Citation on PubMed
or
Free article on PubMed Central
Hallam TM, Bourtchouladze R. Rubinstein-Taybi syndrome: molecular findings and
therapeutic approaches to improve cognitive dysfunction. Cell Mol Life Sci. 2006
Aug;63(15):1725-35. doi: 10.1007/s00018-005-5555-8.
Citation on PubMed
Hennekam RC. Rubinstein-Taybi syndrome. Eur J Hum Genet. 2006 Sep;14(9):981-5.
doi: 10.1038/sj.ejhg.5201594. Epub 2006 Jul 26.
Citation on PubMed
Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist D, Papadia F, Bacino
CA, den Dunnen JT, van Ommen GJ, Breuning MH, Hennekam RC, Peters DJ. Genetic
heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300
genes cause disease. Am J Hum Genet. 2005 Apr;76(4):572-80. doi: 10.1086/429130.
Epub 2005 Feb 10.
Citation on PubMed
or
Free article on PubMed Central
Rusconi D, Negri G, Colapietro P, Picinelli C, Milani D, Spena S, Magnani C,
Silengo MC, Sorasio L, Curtisova V, Cavaliere ML, Prontera P, Stangoni G, Ferrero
GB, Biamino E, Fischetto R, Piccione M, Gasparini P, Salviati L, Selicorni A,
Finelli P, Larizza L, Gervasini C. Characterization of 14 novel deletions
underlying Rubinstein-Taybi syndrome: an update of the CREBBP deletion
repertoire. Hum Genet. 2015 Jun;134(6):613-26. doi: 10.1007/s00439-015-1542-9.
Epub 2015 Mar 25.
Citation on PubMed
Stevens CA. Rubinstein-Taybi Syndrome. 2002 Aug 30 [updated 2023 Nov 9]. In:
Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya
A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of
Washington, Seattle; 1993-2024. Available from
http://www.ncbi.nlm.nih.gov/books/NBK1526/
Citation on PubMed
Wiley S, Swayne S, Rubinstein JH, Lanphear NE, Stevens CA. Rubinstein-Taybi
syndrome medical guidelines. Am J Med Genet A. 2003 Jun 1;119A(2):101-10. doi:
10.1002/ajmg.a.10009.
Citation on PubMed
The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.
Official websites use .gov
A
.gov
website belongs to an official government
              organization in the United States.
Secure .gov websites use HTTPS
A
lock
(
Lock
Locked padlock icon
) or
https://
means youâ€™ve safely connected to
              the .gov website. Share sensitive information only on official,
              secure websites.</content></page>